查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470946

mRNA 平台市场：按 mRNA 类型、适应症、应用和最终用户划分 - 2024-2030 年全球预测

mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年mRNA平台市场规模为135.2亿美元，2024年达163.3亿美元，预计2030年将达到527.1亿美元，复合年增长率为21.44%。

mRNA（传讯RNA）平台是医学和生物技术领域的一种新方法，主要用于疫苗和治疗方法的开发。 mRNA 充当细胞中 DNA 和各种身体功能所必需的蛋白质之间的分子中介。 mRNA 平台利用合成 mRNA 引导细胞产生特定蛋白质，例如触发免疫反应或刺激细胞修復，而不会改变细胞的 DNA。 mRNA 平台具有加速疫苗开发和生产的能力，由于全球对有效、快速生产疫苗的需求不断增长，对 mRNA 平台的需求也不断增加。只需改变疫苗中 mRNA 的序列，即可客製化 mRNA 疗法来对抗从感染疾病到癌症等多种疾病。这种多功能性为针对各种病症的个人化医疗和治疗方法开闢了新途径。然而，mRNA疫苗和治疗药物需要超低温储存才能保持稳定性，这给配送带来了挑战，特别是在基础设施有限的地区。将 mRNA 有效地递送至细胞而不发生降解是一个相当大的障碍。研究人员不断发现和改进脂质奈米颗粒和其他递送方法来保护 mRNA，直到其到达目标细胞。除了预防性疫苗外，mRNA 技术也正在研究用于癌症治疗、遗传性疾病和自体免疫疾病等治疗应用。

主要市场统计
基准年[2023] 135.2亿美元
预测年份 [2024] 163.3亿美元
预测年份 [2030] 527.1亿美元
复合年增长率（%） 21.44%

mRNA 类型：核苷修饰的 mRNA 可以透过减少副作用和提高稳定性来平衡免疫反应的有效性。

核苷修饰的 mRNA 会改变 RNA 的组成部分（核苷），以逃避人体的自然防御，这种防御会快速降解 mRNA 或引发不必要的免疫反应。透过修饰这些核苷，科学家可以提高 mRNA 的稳定性和翻译能力，从而使治疗和疫苗讯息更有效地传递到人类细胞。这种类型的 mRNA 已广泛用于 COVID-19 疫苗的开发，因为它能有效引发强烈且持久的免疫反应，且副作用最小。自我扩增的mRNA通常源自于正链RNA病毒的基因组，并且具有在宿主细胞内自我复製的独特能力。这种放大过程意味着可以施用更小的剂量，这可能会降低製造成本并提高可用性。这种 mRNA 不仅编码感兴趣的抗原（例如，需要产生免疫反应的病毒部分），还编码病毒复製机制，允许长期产生抗原，使其更能诱导强烈的免疫反应。未修饰的 mRNA 是用于医学应用的最简单的 mRNA 形式。它不像核苷修饰的 mRNA 那样经历核苷修饰。虽然这使得产生 mRNA 变得更容易，但未修饰的 mRNA 更容易降解，并可能诱导更强的先天免疫反应，为免疫系统提供强大的刺激，但也可能产生副作用。

最终用户：製药公司广泛参与 mRNA 平台的营销和许可。

医院和诊所主要使用基于 mRNA 的治疗和疫苗作为患者照护服务的一部分。他们处于使用 mRNA 平台开发的疫苗的第一线，并在公共卫生工作中发挥关键作用，特别是在大流行期间。此外，医院可以在专门护理下提供针对某些疾病的基于 mRNA 的治疗方法。製药公司正在为基于 mRNA 的药物和疫苗的开发、测试和商业化做出重大贡献。他们正在大力投资研发 (R&D)，以探索 mRNA 技术在治疗多种疾病方面的潜力，包括感染疾病以及癌症和遗传性疾病。这些公司处理成功的 mRNA治疗方法的临床试验、监管核准和大规模生产的复杂过程。因此，製药公司是推进 mRNA 平台并将新治疗方法从实验室推向市场的关键机构。研发机构和学术机构进行基础研究，以了解细胞中 mRNA 的机制，探索改善 mRNA 递送和稳定性的创新方法，并开发该技术的新应用。这些研究机构经常与製药公司合作，提供进一步开发基于 mRNA 的治疗方法所需的基础知识。儘管这些机构不参与商业化过程，但它们在扩大对 mRNA 及其潜在应用的科学理解方面所发挥的作用是有价值的。

区域洞察

美洲，特别是美国和加拿大，由于医疗保健支出高、医疗保健基础设施完善以及对研究和创新的高度重视，为 mRNA 平台呈现出成熟的格局。美洲地区是多家生物技术和製药公司的所在地，这些公司经常投资研发项目，以提高 mRNA 平台的安全性、效率和性能。欧盟国家在支持 mRNA 研究和产品核可的法律规范方面处于领先地位。英国、德国和法国等国家在政府、学术界和私营部门之间的合作推动下拥有强大的生物技术部门。欧洲药品管理局 (EMA) 在促进基于 mRNA 的治疗方法的快速核准方面发挥着至关重要的作用。亚太地区是 mRNA 平台技术快速发展的地区，以中国、日本和印度为首。该地区人口众多，对疫苗和治疗方法（包括 mRNA 平台）有巨大需求。政府对改善医疗基础设施的支持非常重要，而对先进治疗方法的认识的提高为 mRNA 平台的扩展提供了重大机会。亚太地区作为疫苗和药物治疗药物製造地的战略地位也为加速 mRNA 平台的采用提供了有利的框架。

FPNV定位矩阵

FPNV定位矩阵对于评估mRNA平台市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对 mRNA 平台市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.mRNA平台市场的市场规模与预测是多少？

2. mRNA 平台市场预测期间需要考虑投资的产品、细分市场、应用程式和领域有哪些？

3.mRNA平台市场的技术趋势和法规结构是什么？

4.mRNA平台市场主要厂商的市场占有率为何？

5.进入mRNA平台市场合适的形式和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病对治疗药物和疫苗的需求迅速增加
      • 需要缩短疫苗开发和商业化时间
    • 抑制因素
      • 製造和商业途径优化的复杂性
    • 机会
      • 市值和公共资金的增加
      • 按需疫苗开发中 mRNA 技术的最佳化
    • 任务
      • 供应物流的监理风险和障碍较高
  • 市场区隔分析
    • mRNA类型：核苷修饰的mRNA能够平衡免疫反应的有效性并减少副作用，并提高稳定性。
    • 最终用户：製药公司广泛参与 mRNA 平台的营销和许可
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 mRNA 平台市场：依 mRNA 类型

  • 核苷修饰的mRNA
  • 自我扩增mRNA
  • 未修饰的mRNA

第 7 章 mRNA 平台市场：依迹象分类

  • 自体免疫疾病
  • 癌症
  • 感染疾病
  • 罕见疾病
  • 呼吸系统疾病

第八章 mRNA 平台市场：依应用分类

  • 治疗药物
  • 疫苗

第 9 章 mRNA 平台市场：依最终用户划分

  • 医院/诊所
  • 製药公司
  • 研究/学术机构

第十章美洲mRNA平台市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太mRNA平台市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲/中东/非洲mRNA平台市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • VBI Vaccines Inc.在加拿大政府的支持下在mRNA疫苗技术上取得突破
    • 提升医疗保健的未来：mRNA 药物的先锋联盟
    • Sensible Biotechnologies 和 Gingo Bioworks 组成策略联盟，彻底改变 mRNA 生产
  • 战略分析和建议

第14章竞争组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-374DB5A05ED7

[194 Pages Report] The mRNA Platform Market size was estimated at USD 13.52 billion in 2023 and expected to reach USD 16.33 billion in 2024, at a CAGR 21.44% to reach USD 52.71 billion by 2030.

The mRNA (messenger RNA) platform is a novel approach in the field of medicine and biotechnology, primarily utilized for the development of vaccines and therapeutics. mRNA serves as a molecular intermediary between the DNA in cells and the proteins that are essential for various bodily functions. The mRNA platform leverages synthetic mRNA to instruct cells to produce specific proteins that can trigger an immune response or stimulate cell repair without altering the cell's DNA. The ability of mRNA platforms to accelerate the development and production of vaccines and the rising global need to effectively and quickly produce vaccines has driven the need for mRNA platforms. mRNA therapies can be tailored to fight a wide array of diseases, from infectious diseases to cancer, by simply modifying the mRNA sequence the vaccines carry. This versatility opens up new avenues in personalized medicine and treatments for various conditions. However, mRNA vaccines and therapeutics require ultra-cold storage to remain stable, presenting logistical challenges in distribution, particularly in regions with limited infrastructure. Efficiently delivering mRNA into cells without degradation is a considerable hurdle. Researchers are continuously working on finding and improving lipid nanoparticles and other delivery methods to protect the mRNA until it reaches the target cells. Beyond preventive vaccines, mRNA technology is being explored for therapeutic applications, including cancer treatment, genetic disorders, and autoimmune diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 13.52 billion
Estimated Year [2024] USD 16.33 billion
Forecast Year [2030] USD 52.71 billion
CAGR (%) 21.44%

mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability

Nucleoside-modified mRNA involves the alteration of RNA building blocks (nucleosides) to evade the body's natural defenses, which might otherwise rapidly degrade the mRNA or trigger an unwanted immune response. By modifying these nucleosides, scientists can enhance the stability and translational capacity of the mRNA, making it more effective in delivering the therapeutic or vaccine message to the body's cells. This type of mRNA has been widely used in developing COVID-19 vaccines due to its efficiency in producing a strong and lasting immune response with minimal side effects. Self-amplifying mRNA, often derived from the genome of positive-strand RNA viruses, has the unique ability to replicate itself within the host cells. This amplification process means that smaller doses can be administered, potentially reducing production costs and improving accessibility. In addition to encoding the antigen of interest (such as parts of a virus against which an immune response is desired), this mRNA also encodes the viral replication machinery, enabling the prolonged production of the antigen and thereby inducing a stronger and longer-lasting immune response. Unmodified mRNA is the most straightforward form of mRNA used in medical applications. It does not undergo the nucleoside modifications seen in nucleoside-modified mRNA. While this simplifies its production, unmodified mRNA is more susceptible to degradation and may induce stronger innate immune responses, providing a potent stimulant for the immune system but also potentially leading to adverse effects.

End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms

Hospitals and clinics primarily use mRNA-based treatments and vaccines as part of their patient care services. They are at the forefront of administering vaccines developed using the mRNA platform, playing a crucial role in public health initiatives, especially during pandemics. Additionally, mRNA-based therapies for certain diseases might be provided in hospital settings under specialized care. Pharmaceutical companies are instrumental in the development, testing, and commercialization of mRNA-based drugs and vaccines. They invest heavily in research and development (R&D) to explore the potential of mRNA technology in treating a wide array of diseases, beyond just infectious diseases to include cancer and genetic disorders. These companies handle the complex processes of clinical trials, regulatory approvals, and mass production of successful mRNA treatments. Thus, pharmaceutical companies are key institutions in advancing the mRNA platform and bringing new therapies from the lab to the market. Research and academic institutions conduct fundamental research to understand the mechanism of mRNA within the cell, explore innovative approaches to improve mRNA delivery and stability, and develop new applications for this technology. These institutions often collaborate with pharmaceutical companies and provide the foundational knowledge necessary for further development of mRNA-based treatments. While they are not involved in the commercialization process, their role in expanding the scientific understanding of mRNA and its potential applications is valuable.

Regional Insights

The Americas, particularly the United States and Canada, present a mature landscape for the mRNA platform, driven by the high healthcare expenditure, sophisticated healthcare infrastructure, and a strong focus on research and innovation. The Americas region is characterized by the presence of several biotechnology and pharmaceutical companies that frequently invest in R&D programs to improve the safety, efficiency, and performance of mRNA platforms. EU countries lead in regulatory frameworks supporting mRNA research and product approvals. Nations such as the U.K., Germany, and France have strong biotech sectors that are propelled by collaborative efforts between governments, academia, and private sectors. The European Medicine Agency (EMA) plays a pivotal role in facilitating the swift approval of mRNA-based treatments. APAC region is a rapidly evolving landscape for mRNA platform technologies driven by China, Japan, and India. The region's significant population base presents a vast need for vaccines and therapeutic treatments, including mRNA platforms. Government support for improving the healthcare infrastructure notably and a growing awareness of advanced treatment modalities present significant opportunities for the expansion of mRNA platforms. APAC's strategic position as a manufacturing hub for vaccines and drug therapeutics also serves to create a conducive framework for driving the adoption of mRNA platforms.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the mRNA Platform Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the mRNA Platform Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Accanis Biotech F&E GmbH & Co KG, Aldevron, LLC by Danaher Corporation, Arcturus Therapeutics, Inc., Argos Therapeutics, Inc., AstraZeneca plc, Avectas Limited, BioNTech SE, Catalent, Inc., CRISPR Therapeutics AG, CureVac N.V., Daiichi Sankyo, Dicerna Pharmaceuticals, Inc by Novo Nordisk A/S, eTheRNA, ethris GmbH, Gritstone bio, In-Cell-Art, Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Tiba Biotech LLC, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the mRNA Platform Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • mRNA Type
    • Nucleoside-Modified mRNA
    • Self-Amplifying mRNA
    • Unmodified mRNA
  • Indication
    • Autoimmune Diseases
    • Cancer
      • Personalized Treatment
      • Single Cancer Focussed
    • Infectious Diseases
    • Rare Diseases
    • Respiratory Diseases
  • Application
    • Therapeutics
    • Vaccines
  • End-User
    • Hospitals & Clinics
    • Pharmaceutical Companies
    • Research & Academic Institutiions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the mRNA Platform Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the mRNA Platform Market?

3. What are the technology trends and regulatory frameworks in the mRNA Platform Market?

4. What is the market share of the leading vendors in the mRNA Platform Market?

5. Which modes and strategic moves are suitable for entering the mRNA Platform Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in demand of therapies and vaccines due to the infectious diseases
      • 5.1.1.2. Need to reduce vaccine development and commercialization timeline
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity in optimising manufacturing and commercial pathways
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased market capitalization and public funding
      • 5.1.3.2. mRNA technology optimization on development of on-demand vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. High regulatory risk and hurdles in supply logistics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
    • 5.2.2. End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. mRNA Platform Market, by mRNA Type

  • 6.1. Introduction
  • 6.2. Nucleoside-Modified mRNA
  • 6.3. Self-Amplifying mRNA
  • 6.4. Unmodified mRNA

7. mRNA Platform Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Cancer
  • 7.4. Infectious Diseases
  • 7.5. Rare Diseases
  • 7.6. Respiratory Diseases

8. mRNA Platform Market, by Application

  • 8.1. Introduction
  • 8.2. Therapeutics
  • 8.3. Vaccines

9. mRNA Platform Market, by End-User

  • 9.1. Introduction
  • 9.2. Hospitals & Clinics
  • 9.3. Pharmaceutical Companies
  • 9.4. Research & Academic Institutiions

10. Americas mRNA Platform Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific mRNA Platform Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa mRNA Platform Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. VBI Vaccines Inc.'s Groundbreaking Advancement in mRNA Vaccine Technology with Government of Canada Support
    • 13.3.2. Elevating the Future of Healthcare: The Pioneering Alliance for mRNA Medicines
    • 13.3.3. Sensible Biotechnologies and Ginkgo Bioworks Forge Strategic Alliance for Revolutionizing mRNA Production
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MRNA PLATFORM MARKET RESEARCH PROCESS
  • FIGURE 2. MRNA PLATFORM MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MRNA PLATFORM MARKET DYNAMICS
  • FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MRNA PLATFORM MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY UNMODIFIED MRNA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA PLATFORM MARKET SIZE, BY PERSONALIZED TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MRNA PLATFORM MARKET SIZE, BY PERSONALIZED TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MRNA PLATFORM MARKET SIZE, BY SINGLE CANCER FOCUSSED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MRNA PLATFORM MARKET SIZE, BY SINGLE CANCER FOCUSSED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MRNA PLATFORM MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL MRNA PLATFORM MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL MRNA PLATFORM MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL MRNA PLATFORM MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL MRNA PLATFORM MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. ARGENTINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 69. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. BRAZIL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CANADA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. MEXICO MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. UNITED STATES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES MRNA PLATFORM MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. CHINA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. INDIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 153. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. INDONESIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. TAIWAN MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. THAILAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. VIETNAM MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 255. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. DENMARK MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. EGYPT MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 275. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. FINLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 286. FRANCE MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. GERMANY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 305. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. ISRAEL MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 315. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. ITALY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 334. NETHERLANDS MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 335. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 336. NIGERIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 337. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 338. NIGERIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 339. NIGERIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 340. NIGERIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 341. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 342. NIGERIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 343. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 344. NIGERIA MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 345. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. NORWAY MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 348. NORWAY MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 349. NORWAY MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 350. NORWAY MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 351. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 352. NORWAY MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 353. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 354. NORWAY MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 355. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 356. POLAND MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 357. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 358. POLAND MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 359. POLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 360. POLAND MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 361. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 362. POLAND MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 363. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 364. POLAND MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 365. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 366. QATAR MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 367. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 368. QATAR MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 369. QATAR MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 370. QATAR MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 371. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 372. QATAR MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 373. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 374. QATAR MRNA PLATFORM MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 375. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2018-2023 (USD MILLION)
  • TABLE 376. RUSSIA MRNA PLATFORM MARKET SIZE, BY MRNA TYPE, 2024-2030 (USD MILLION)
  • TABLE 377. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 378. RUSSIA MRNA PLATFORM MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 379. RUSSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
  • TABLE 380. RUSSIA MRNA PLATFORM MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
  • TABLE 381. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 382. RUSSIA MRNA PLATFORM MARKET SIZE, BY APPLICATION, 2024-203